NASDAQ:LMAT - US5255582018 - Common Stock
The current stock price of LMAT is 95.365 USD. In the past month the price increased by 17.68%. In the past year, price increased by 5.62%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.07 | 230.89B | ||
ISRG | INTUITIVE SURGICAL INC | 58.79 | 169.67B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.28 | 156.32B | ||
SYK | STRYKER CORP | 30.46 | 149.64B | ||
MDT | MEDTRONIC PLC | 16.78 | 119.05B | ||
BDX | BECTON DICKINSON AND CO | 13.52 | 55.31B | ||
IDXX | IDEXX LABORATORIES INC | 53.88 | 51.77B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.65 | 47.75B | ||
RMD | RESMED INC | 28.74 | 40.19B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.82 | 33.66B | ||
DXCM | DEXCOM INC | 44.32 | 29.55B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.42 | 26.56B |
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 651 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. The company also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
LEMAITRE VASCULAR INC
63 2nd Ave
Burlington MASSACHUSETTS 01803 US
CEO: George W. LeMaitre
Employees: 658
Phone: 17812212266
The current stock price of LMAT is 95.365 USD. The price increased by 0.1% in the last trading session.
The exchange symbol of LEMAITRE VASCULAR INC is LMAT and it is listed on the Nasdaq exchange.
LMAT stock is listed on the Nasdaq exchange.
17 analysts have analysed LMAT and the average price target is 106.87 USD. This implies a price increase of 12.07% is expected in the next year compared to the current price of 95.365. Check the LEMAITRE VASCULAR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LEMAITRE VASCULAR INC (LMAT) has a market capitalization of 2.16B USD. This makes LMAT a Mid Cap stock.
LEMAITRE VASCULAR INC (LMAT) currently has 658 employees.
LEMAITRE VASCULAR INC (LMAT) has a support level at 95.36 and a resistance level at 100.12. Check the full technical report for a detailed analysis of LMAT support and resistance levels.
The Revenue of LEMAITRE VASCULAR INC (LMAT) is expected to grow by 13.91% in the next year. Check the estimates tab for more information on the LMAT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LEMAITRE VASCULAR INC (LMAT) has a dividend yield of 0.84%. The yearly dividend amount is currently 0.64. Check the full fundamental report for a detailed analysis of LMAT dividend history, reliability and sustainability.
LEMAITRE VASCULAR INC (LMAT) will report earnings on 2025-10-29, after the market close.
The PE ratio for LEMAITRE VASCULAR INC (LMAT) is 46.29. This is based on the reported non-GAAP earnings per share of 2.06 and the current share price of 95.365 USD. Check the full fundamental report for a full analysis of the valuation metrics for LMAT.
The outstanding short interest for LEMAITRE VASCULAR INC (LMAT) is 6.44% of its float. Check the ownership tab for more information on the LMAT short interest.
ChartMill assigns a technical rating of 8 / 10 to LMAT. When comparing the yearly performance of all stocks, LMAT turns out to be only a medium performer in the overall market: it outperformed 67.69% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to LMAT. LMAT gets an excellent profitability rating and is at the same time showing great financial health properties.
Over the last trailing twelve months LMAT reported a non-GAAP Earnings per Share(EPS) of 2.06. The EPS increased by 23.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 20.08% | ||
ROA | 8.16% | ||
ROE | 12.99% | ||
Debt/Equity | 0.46 |
17 analysts have analysed LMAT and the average price target is 106.87 USD. This implies a price increase of 12.07% is expected in the next year compared to the current price of 95.365.
For the next year, analysts expect an EPS growth of 20.02% and a revenue growth 13.91% for LMAT